Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Condition:   Metastatic Non-Small Cell Lung Cancer Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Docetaxel Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials